2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 848

Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Abstract Number: 849

A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Abstract Number: 850

Incidence and Predictors of Severe Heart Disease in Systemic Sclerosis
Abstract Number: 851

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
Abstract Number: 852

Health-Related Quality of Life in Early Systemic Sclerosis
Abstract Number: 853

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases
Abstract Number: 854

Nationwide Incidence of Anti Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis in Iceland
Abstract Number: 855

Seasonality in ANCA-Associated Vasculitis
Abstract Number: 856

Elderly Versus Younger Patients with ANCA-Associated Vasculitis
Abstract Number: 857

Prognosis Value of Geriatric Assessment Scales in Older Adults with New Onset ANCA-Associated Vasculitis: A Pilot Retrospective Study
Abstract Number: 858

Stimulated Renal Glomerular Endothelial Cells Were Damaged By Fiber-like NETs Released By Neutrophils in ANCA-Associated Vasculitis
Abstract Number: 859

Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis
Abstract Number: 860

Neutrophil/Lymphocyte Ratio: Could It be a Prognostic Indicator for Renal Outcome in Patients with Granulomatosis with Polyangiitis?
Abstract Number: 861

ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?
Abstract Number: 862

Discriminative Performance of Nasal Endoscopic Findings and History Items in Patients with Granulomatosis with Polyangiitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].